|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| |  |  | | --- | --- | | |  | | --- | |  | | | |  | | --- | |  | | PSNC Newsletter | | Wednesday 5th October 2022 | | |  | | |  |  |  | | --- | --- | --- | |  |  |  | |  | This newsletter from PSNC is sent on Mondays, Wednesdays and Fridays. It contains important information for those that work in the community pharmacy sector. In this update: PQS 2022/23 details released; TAPR update; MYS change for flu vaccine submissions; MHRA Drug Safety Update.PQS: publication of further details on the 2022/23 scheme Further details on the Pharmacy Quality Scheme (PQS) 2022/23 have been published today on the NHS Business Services Authority (NHSBSA) website. The details have been published as a separate Determination; they will be included in the Drug Tariff from November 2022.  Priority points to note include details of the aspiration payment window and the Respiratory Domain criteria, both of which begin on Monday 10th October.  PSNC's [**PQS hub page**](https://psnc.us7.list-manage.com/track/click?u=86d41ab7fa4c7c2c5d7210782&id=4f32fa3a41&e=d19e9fd41c) has been updated to reflect the additional information that has now been published on the Scheme, and additional resources and FAQs to support contractors will continue to be added to this page.  [**Learn more about the 2022/23 PQS**](https://psnc.us7.list-manage.com/track/click?u=86d41ab7fa4c7c2c5d7210782&id=8d0d6d1c99&e=d19e9fd41c) TAPR Update: PSNC takes initial governance, levy and influencing decisions PSNC is progressing work to enhance its negotiating capacity, strengthen its governance, develop a new vision and strategy for the sector, and more, in line with the Transforming Pharmacy Representation (TAPR) programme.   At its meeting in September, PSNC Members considered and voted on changes to the PSNC Constitution and to reduce the Committee size, as well as discussing the principles for collecting levies. Steps have also been taken to increase PSNC’s influencing capacity, with the appointment of a political campaigning agency following a tender process.  [**Read the TAPR update**](https://psnc.us7.list-manage.com/track/click?u=86d41ab7fa4c7c2c5d7210782&id=43b831fae7&e=d19e9fd41c) Change to a flu vaccine description on MYS A change has been made on Manage Your Service (MYS) for flu vaccine submissions. The description for the quadrivalent vaccine by Seqirus has been replaced with 'Cell-based quadrivalent influenza vaccine (surface antigen, inactivated) suspension for injection 0.5ml pre-filled syringes, by Seqirus UK'. This reflects the generic version of the vaccine that is being administered, in line with the marketed vaccines for 2022/23.  [**Login to MYS to submit your flu vaccine claims**](https://psnc.us7.list-manage.com/track/click?u=86d41ab7fa4c7c2c5d7210782&id=4f566d6af6&e=d19e9fd41c) MHRA Drug Safety Update A new Medicines and Healthcare products Regulatory Agency (MHRA) Drug Safety Update has been published. The latest MHRA Drug Safety Update includes articles on Methylphenidate long-acting (modified-release) preparations, COVID-19 vaccines and medicines and more.  [**Read the September MHRA Drug Safety Update**](https://psnc.us7.list-manage.com/track/click?u=86d41ab7fa4c7c2c5d7210782&id=5f39542b0a&e=d19e9fd41c) |  | |  |  |  | | |
| |  |  |  | | --- | --- | --- | | |  | | --- | | Pharmaceutical Services Negotiating Committee      14 Hosier Lane, London, EC1A 9LQ Tel: 0203 1220 810 | Email: [**info@psnc.org.uk**](mailto:info@psnc.org.uk) | |  | | |

